1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

 
• By Joseph Haas

A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.

Weight loss
Veru hopes enobosarm may show potential as add-on therapy in weight loss • Source: Shutterstock

Veru Inc. started out focused mainly on cancer supportive therapy, but now thinks it has identified a new direction for its lead candidate, the selective androgen receptor modulator (SARM) enobosarm, by investigating its potential as add-on therapy to weight-loss drugs to prevent muscle loss and possibly even aid in the weight-loss process.

Key Takeways

  • Clinical-stage Veru is looking to jump into the weight-loss therapy space by positioning enobosarm as add-on therapy to GLP-1 agents to protect against muscle loss that can accompany weight loss.

  • Enobosarm is also in Phase III to treat second-line metastatic breast cancer in combination with Lilly’s Verzenio

The Miami-based firm said on 4 October that it hopes to initiate a Phase IIb study in early 2024 of enobosarm in tandem with GLP-1 agonists, such as semaglutide (Novo Nordisk A/S’s Ozempic/Wegovy) and Eli Lilly and Company’s Mounjaro (tirzepatide), a dual GLP-1/GIP agonist that is approved to treat type 2 diabetes and is under review at the US Food and Drug Administration for weight loss

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.